KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Non-Current Assets (2016 - 2025)

Jazz Pharmaceuticals has reported Non-Current Assets over the past 16 years, most recently at $7.5 billion for Q4 2025.

  • Quarterly results put Non-Current Assets at $7.5 billion for Q4 2025, up 1.49% from a year ago — trailing twelve months through Dec 2025 was $30.1 billion (down 2.02% YoY), and the annual figure for FY2025 was $7.5 billion, up 1.49%.
  • Non-Current Assets for Q4 2025 was $7.5 billion at Jazz Pharmaceuticals, down from $7.6 billion in the prior quarter.
  • Over the last five years, Non-Current Assets for JAZZ hit a ceiling of $10.3 billion in Q2 2021 and a floor of $3.6 billion in Q1 2021.
  • Median Non-Current Assets over the past 5 years was $7.9 billion (2023), compared with a mean of $8.0 billion.
  • Biggest five-year swings in Non-Current Assets: surged 172.55% in 2021 and later dropped 20.68% in 2022.
  • Jazz Pharmaceuticals' Non-Current Assets stood at $9.7 billion in 2021, then decreased by 15.05% to $8.2 billion in 2022, then dropped by 3.3% to $8.0 billion in 2023, then decreased by 7.22% to $7.4 billion in 2024, then increased by 1.49% to $7.5 billion in 2025.
  • The last three reported values for Non-Current Assets were $7.5 billion (Q4 2025), $7.6 billion (Q3 2025), and $7.6 billion (Q2 2025) per Business Quant data.